Muscle function enhancing peptide
AssigneeUniversitatsklinikum Heidelberg
InventorsPatrick Most, Mirko Voelkers, Hugo Katus, Andrew Remppis
Life of this patent
Estimating the term…
Abstract
The present invention relates to a peptide comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptide for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical composition comprising said peptide and a method for treating or preventing disorders associated with muscular malfunction using said peptide or said pharmaceutical composition.
Claims22
A method for treating a disorder associated with muscular malfunction comprising administering to an individual in need thereof a pharmaceutical composition consisting of a peptide comprising a muscle function enhancing amino acid sequence comprising the amino acid sequence:
- [V/I]-[V/I]-[L/M-[V/I/M]-A/G/S]-[A/V]-L-[T/A]-[V/A/I]-[A/M/V] (SEQ ID NO:
- 3),
- wherein the muscle function enhancing amino acid sequence does not contain more than 10 continuous amino acids of the carboxy-terminal amino acids of an S100A1 protein, the peptide has a total length of maximally 100 amino acids, and the peptide exhibits a positive inotropic action;
- wherein said peptide further comprises a hydrophilic motif, wherein said hydrophilic motif comprises the hydrophilic amino acid motif:
- Λ4-Θ2,
- wherein Λ is in each instance independently selected from aspartate, glutamate, lysine, and arginine and Θ is an α-helix interrupter,
- in an amount sufficient to treat said disorder of said individual and
- optionally a pharmaceutically acceptable excipient, carrier, and/or diluent.
A method for treating a disorder associated with muscular malfunction comprising administering to an individual in need thereof
- a peptide comprising a muscle function enhancing amino acid sequence comprising the amino acid sequence:
- [V/I]-[V/I]-[L/M]-[V/I/M][A/G/S]-[A/V]-L-[T/A]-[V/A/I][A/M/V] (SEQ ID NO:
- 3),
- wherein the muscle function enhancing amino acid sequence does not contain more than 10 continuous amino acids of the carboxy-terminal amino acids of an S100A1 protein, the peptide has a total length of maximally 100 amino acids, and the peptide exhibits a positive inotropic action;
- wherein said peptide further comprises a hydrophilic motif, wherein said hydrophilic motif comprises the hydrophilic amino acid motif:
- Λ4-Θ2,
- wherein Λ is in each instance independently selected from aspartate, glutamate, lysine, and arginine and Θ is an α-helix interrupter, in an amount sufficient to treat said disorder of said individual and
- optionally comprising a pharmaceutically acceptable excipient, carrier, and/or diluent.
A method for treating a disorder associated with muscular malfunction comprising administering to an individual in need thereof
- a peptide comprising a muscle function enhancing amino acid sequence comprising the amino acid sequence:
- [V/I]-[V/I]-[L/M]-[V/I/M]-[A/G/S]-[A/V]-L-[T/A]-[V/A/I]-[A/M/V] (SEQ ID NO:
- 3),
- wherein the muscle function enhancing amino acid sequence does not contain more than 10 continuous amino acids of the carboxy-terminal amino acids of an S100A1 protein, the peptide has a total length of maximally 100 amino acids, and the peptide exhibits a positive inotropic action;
- wherein said peptide further comprises a hydrophilic motif, wherein said hydrophilic motif comprises the hydrophilic amino acid motif:
- Λ4-Θ2,
- wherein Λ is in each instance independently selected from aspartate, glutamate, lysine, and arginine and Θ is an α-helix interrupter, in an amount sufficient to treat said disorder of said individual and optionally comprising a pharmaceutically acceptable excipient, carrier, and/or diluent, wherein said peptide is administered daily for 4 weeks.
Dependencies are inferred from the claim text.